Epidemiology of perforating peptic ulcer: A population-based retrospective study over 40 years

Table 1 Trends in patient characteristics according to decade of treatment, n (%)

n = 209	1978–1987 (n = 38)	1988–1997 (n = 64)	1998–2007 (n = 62)	2008-2017 (n = 45)	P value
Sex
Women	14 (36.8)	26 (40.6)	31 (50.0)	25 (55.6)	0.049a
Men	24 (63.2)	38 (59.4)	31 (50.0)	20 (44.4)
Incidence (No./100000)
Women	3.3 (1.8 to 5.5)	6.0 (3.9 to 8.8)	7.0 (4.8 to 9.9)	5.3 (3.4 to 7.8)	0.14b
Men	5.5 (3.6 to 8.3)	8.7 (6.2 to 12.0)	7.0 (4.8 to 10.0)	4.2 (2.6 to 6.5)	0.32b
Age, mean ± SD, years	62 ± 17	64 ± 16	67 ± 16	69 ± 17	0.018c
Hours from symptom debut until admission, mean ± SD)	7 ± 9	8 ± 12	16 ± 29	13 ± 14	0.019c
ASA class
II	30 (78.9)	46 (71.9)	33 (53.2)	24 (53.3)	0.001d
III	6 (15.8)	13 (20.3)	19 (30.6)	11 (24.2)
IV	2 (5.3)	5 (7.8)	10 (16.1)	9 (20.0)
V	0	0	0	1 (2.2)
Ulcer localisation
Gastric	25 (65.8)	27 (42.2)	26 (41.9)	19 (42.2)	0.059a
Duodenal	13 (34.2)	37 (57.8)	36 (58.1)	26 (57.8)
Past ulcer history	5 (13.2)	25 (39.1)	16 (26.2)	0	0.022a
Smoker at present	19 (57.6)	40 (64.5)	27 (49.1)	26 (59.1)	0.89a
NSAID use	4 (10.5)	11 (17.2)	19 (31.1)	8 (17.8)	0.18a
Steroid use	2 (5.3)	2 (3.1)	7 (11.5)	3 (6.7)	0.42a
Salicylate use	2 (5.3)	4 (6.3)	10 (16.4)	8 (17.8)	0.025a
Charlson Comorbidity index
0	26 (68.4)	37 (57.8)	29 (46.8)	18 (40.0)	0.003d
1	5 (13.2)	22 (34.4)	24 (38.7)	13 (28.9)
2+	7 (18.4)	5 (7.8)	9 (14.5)	14 (31.1)

^aCochran-Armitage exact trend test.

^bPoisson regression with calendar year as covariate.

^cJonckheere-Terpstra exact test.

^dOrdered logistic regression analysis. SD: Standard deviation; ASA: American Society of Anesthesiologists; NSAID: Non-steroidal anti-inflammatory drugs.